Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Chen Chen, Yanlong Liu & Binbin Cui. (2021) Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment. Human Vaccines & Immunotherapeutics 17:6, pages 1555-1567.
Read now
Read now
Articles from other publishers (26)
XiaoYu Wang, Xiaoyan Mo, Zhuolin Yang & Changlin Zhao. (2024) Qntrolling the LncRNA HULC-Tregs-PD-1 axis inhibits immune escape in the tumor microenvironment. Heliyon 10:7, pages e28386.
Crossref
Crossref
Sabine Groeger & Joerg Meyle. (2024) The role of programmed death receptor (PD‐)1/PD‐ligand (L)1 in periodontitis and cancer. Periodontology 2000.
Crossref
Crossref
Jin Shang, Lin Li, Chunyou Lai, Tianhang Feng, Yutong Yao, Deyuan Zhong, Yuxin Liang, Xiaolun Huang, Qinyan Yang & Ying Shi. (2023) Single-cell profiling reveals the heterogeneity of NK cells during anti-PD-1 therapy in non-small-cell lung cancer. International Immunopharmacology 124, pages 110743.
Crossref
Crossref
Xiangyong Liu, Chao Yan, Aijie Yang, Enhao Yu, Jie Yu, Chunyang Zhou, Yun Wang, Kai Wang, Ying Sun & Yufeng Cheng. (2023)
Efficacy of anti-programmed cell death protein 1 monoclonal antibody combined with bevacizumab and/or
Pseudomonas aeruginosa
injection in transplanted tumor of mouse forestomach carcinoma cell gastric cancer in mice and its mechanism in regulating tumor immune microenvironment
. Clinical and Experimental Immunology 213:3, pages 328-338.
Crossref
Crossref
Dani Ran Castillo, Won Jin Jeon, Daniel Park, Bryan Pham, Chieh Yang, Bowon Joung, Jin Hyun Moon, Jae Lee, Esther G. Chong, Kiwon Park, Mark E. Reeves, Penelope Duerksen-Hughes, Hamid R. Mirshahidi & Saied Mirshahidi. (2023) Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management. International Journal of Molecular Sciences 24:14, pages 11547.
Crossref
Crossref
Xinyuan Gao, Yulan Nie & Yuhao Yang. (2023) Current Program in Anti-tumor Immunotherapy: Targeting PD-1/PD-L1 Immune Checkpoint. Highlights in Science, Engineering and Technology 36, pages 312-320.
Crossref
Crossref
Jonathan Peña Avila, Bruno Melo Carvalho & Eliane Campos Coimbra. (2023) A Comprehensive View of the Cancer-Immunity Cycle (CIC) in HPV-Mediated Cervical Cancer and Prospects for Emerging Therapeutic Opportunities. Cancers 15:4, pages 1333.
Crossref
Crossref
Qing Tang, Yun Chen, Xiaojuan Li, Shunqin Long, Yao Shi, Yaya Yu, Wanyin Wu, Ling Han & Sumei Wang. (2022) The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Frontiers in Immunology 13.
Crossref
Crossref
Moataz Reda, Worapol Ngamcherdtrakul, Molly A. Nelson, Natnaree Siriwon, Ruijie Wang, Husam Y. Zaidan, Daniel S. Bejan, Sherif Reda, Ngoc Ha Hoang, Noah A. Crumrine, Justin P. C. Rehwaldt, Akash Bindal, Gordon B. Mills, Joe W. Gray & Wassana Yantasee. (2022) Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment. Nature Communications 13:1.
Crossref
Crossref
Lara Alessandrini, Leonardo Franz, Marta Sbaraglia, Tommaso Saccardo, Filippo Cappello, Alessandro Drigo, Anna Chiara Frigo & Gino Marioni. (2022) Tumor-Stroma Ratio and Programmed Cell Death Ligand 1 Expression in Preoperative Biopsy and Matched Laryngeal Carcinoma Surgical Specimen. International Journal of Molecular Sciences 23:14, pages 8053.
Crossref
Crossref
Qinying Sun, Xiangzhen Wei, Zhonglin Wang, Yan Zhu, Weiying Zhao & Yuchao Dong. (2022) Primary and Acquired Resistance against Immune Check Inhibitors in Non-Small Cell Lung Cancer. Cancers 14:14, pages 3294.
Crossref
Crossref
Keywan Mortezaee & Jamal Majidpoor. (2022) Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy. Cellular Oncology 45:3, pages 333-353.
Crossref
Crossref
Fenglong Bie, He Tian, Nan Sun, Ruochuan Zang, Moyan Zhang, Peng Song, Lei Liu, Yue Peng, Guangyu Bai, Bolun Zhou & Shugeng Gao. (2022) Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC. Frontiers in Oncology 12.
Crossref
Crossref
Keywan Mortezaee & Jamal Majidpoor. (2022) (Im)maturity in Tumor Ecosystem. Frontiers in Oncology 11.
Crossref
Crossref
Wanying Zhao, Yuanzheng Liang & Liang Wang. (2021) Advances in targeting programmed cell death 1/programmed cell death-ligand 1 therapy for hematological malignancies. Aging Pathobiology and Therapeutics 3:4, pages 84-94.
Crossref
Crossref
Kinjal Shah, Amr Al-Haidari, Jianmin Sun & Julhash U. Kazi. (2021) T cell receptor (TCR) signaling in health and disease. Signal Transduction and Targeted Therapy 6:1.
Crossref
Crossref
Leonardo Franz, Lara Alessandrini, Leonardo Calvanese, Giulia Crosetta, Anna Chiara Frigo & Gino Marioni. (2021) Angiogenesis, programmed death ligand 1 (PD-L1) and immune microenvironment association in laryngeal carcinoma. Pathology 53:7, pages 844-851.
Crossref
Crossref
Chushu Li, Hao Chi, Shouyan Deng, Ke Xu, Huanbin Wang, Han Yao, Yungang Wang, Dawei Chen, Xun Guo, Jing-Yuan Fang, Fang He & Jie Xu. (2021) THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy. Journal for ImmunoTherapy of Cancer 9:8, pages e002443.
Crossref
Crossref
Minsu Kwon, Hanul Jung, Gi-Hoon Nam & In-San Kim. (2021) The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy. Journal of Controlled Release 331, pages 321-334.
Crossref
Crossref
Leonardo Franz, Lara Alessandrini, Elena Fasanaro, Piergiorgio Gaudioso, Alessandro Carli, Piero Nicolai & Gino Marioni. (2021) Prognostic impact of neutrophils-to-lymphocytes ratio (NLR), PD-L1 expression, and tumor immune microenvironment in laryngeal cancer. Annals of Diagnostic Pathology 50, pages 151657.
Crossref
Crossref
Anastasia Mpakali & Efstratios Stratikos. (2021) The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy. Cancers 13:1, pages 134.
Crossref
Crossref
Lara Alessandrini, Leonardo Franz, Giancarlo Ottaviano, Maria Grazia Ghi, Cristiano Lanza, Stella Blandamura & Gino Marioni. (2020) Prognostic role of programmed death ligand 1 (PD-L1) and the immune microenvironment in laryngeal carcinoma. Oral Oncology 108, pages 104836.
Crossref
Crossref
Lydia Xenou & Evangelia A. Papakonstanti. (2020) p110δ PI3K as a therapeutic target of solid tumours. Clinical Science 134:12, pages 1377-1397.
Crossref
Crossref
Xingyu Chen, Yi Jin, Lian Gong, Dong He, YaXing Cheng, Mengqing Xiao, Yuxing Zhu, Zhanwang Wang & Ke Cao. (2020) Bioinformatics Analysis Finds Immune Gene Markers Related to the Prognosis of Bladder Cancer. Frontiers in Genetics 11.
Crossref
Crossref
Wen-Ling Lee & Peng-Hui Wang. (2020) Immunology and ovarian cancers. Journal of the Chinese Medical Association 83:5, pages 425-432.
Crossref
Crossref
Abdulaziz B. Hamid & Ruben C. Petreaca. (2020) Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells. Cancers 12:4, pages 927.
Crossref
Crossref